Halbert C L, Standaert T A, Aitken M L, Alexander I E, Russell D W, Miller A D
Fred Hutchinson Cancer Research Centre, Seattle, Washington 98109, USA.
J Virol. 1997 Aug;71(8):5932-41. doi: 10.1128/JVI.71.8.5932-5941.1997.
The ability of recombinant adeno-associated virus (AAV) vectors to integrate into the host genome and to transduce nondividing cells makes them attractive as vehicles for gene delivery. In this study, we assessed the ability of several AAV vectors to transduce airway cells in rabbits by measuring marker gene expression. AAV vectors that transferred either a beta-galactosidase (beta-gal) or a human placental alkaline phosphatase (AP) gene were delivered to one lobe of the rabbit lung by use of a balloon catheter placed under fluoroscopic guidance. We observed vector-encoded beta-gal or AP staining almost exclusively in the epithelial and smooth muscle cells in the bronchus at the region of balloon placement. The overall efficiency of transduction in the balloon-treated bronchial epithelium was low but reached 20% in some areas. The majority of the staining was in ciliated cells but was also observed in basal cells and airway smooth muscle cells. We observed an 80-fold decrease in marker-positive epithelial cells during the 60-day period after vector infusion, whereas the number of marker-positive smooth muscle cells stayed constant. Although treatment with the topoisomerase inhibitor etoposide dramatically enhanced AAV transduction in primary airway epithelial cells in culture, treatment of rabbits did not improve transduction rates in the airway. Vector readministration failed to produce additional transduction events, which correlated with the appearance of neutralizing antibodies. These results indicate that both readministration and immune modulation will be required in the use of AAV vectors for gene therapy to the airway epithelium.
重组腺相关病毒(AAV)载体整合到宿主基因组并转导非分裂细胞的能力使其成为有吸引力的基因递送载体。在本研究中,我们通过测量标记基因表达来评估几种AAV载体转导兔气道细胞的能力。利用置于荧光镜引导下的球囊导管,将携带β-半乳糖苷酶(β-gal)或人胎盘碱性磷酸酶(AP)基因的AAV载体递送至兔肺的一个肺叶。我们观察到载体编码的β-gal或AP染色几乎仅在球囊放置区域支气管的上皮细胞和平滑肌细胞中出现。球囊处理的支气管上皮中转导的总体效率较低,但在某些区域达到了20%。大多数染色出现在纤毛细胞中,但在基底细胞和气道平滑肌细胞中也有观察到。在载体注入后的60天内,我们观察到标记阳性上皮细胞减少了80倍,而标记阳性平滑肌细胞的数量保持不变。虽然用拓扑异构酶抑制剂依托泊苷处理可显著增强培养的原代气道上皮细胞中的AAV转导,但对兔的处理并未提高气道中的转导率。再次给予载体未能产生额外的转导事件,这与中和抗体的出现相关。这些结果表明,在将AAV载体用于气道上皮基因治疗时,需要再次给予载体和免疫调节。